Algert Global’s BioMarin Pharmaceuticals BMRN Stock Holding History

Algert Global’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$6.78M	Sell	118,440 -48,130	-29%	-$2.64M	0.08%	418
2026 Q1	$9.41M	Buy	166,570 +49,540	+42%	+$2.89M	0.14%	222
2025 Q4	$6.96M	Buy	117,030 +76,820	+191%	+$4.18M	0.11%	318
2025 Q3	$2.18M	Buy	40,210 +336	+0.8%	+$19.2K	0.04%	657
2025 Q2	$2.19M	Sell	39,874 -66,004	-62%	-$3.89M	0.05%	605
2025 Q1	$7.48M	Buy	105,878 +63,783	+152%	+$4.29M	0.19%	152
2024 Q4	$2.77M	Buy	+42,095	New	+$2.82M	0.07%	498
2023 Q4	–	Sell	-5,186	Closed	-$459K	–	1136
2023 Q3	$459K	Buy	+5,186	New	+$461K	0.02%	770
2023 Q1	–	Sell	-4,156	Closed	-$430K	–	1144
2022 Q4	$430K	Buy	+4,156	New	+$390K	0.02%	852

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Algert Global's BMRN Position: Q2 2026 in Review

Algert Global reduced its BioMarin Pharmaceuticals (BMRN) stake by 29% in Q2 2026, selling an estimated $2.64M and leaving 118,440 shares worth $6.78M. The position accounts for 0.08% of the portfolio, ranked #418.

Algert Global first reported a position in BMRN in Q4 2022 and has held it in 9 quarters since. The position peaked at $9.41M in Q1 2026. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Algert Global held 118,440 shares of BioMarin Pharmaceuticals worth $6.78M as of Q2 2026.
Algert Global sold 48,130 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $2.64M.
BioMarin Pharmaceuticals made up 0.08% of Algert Global's portfolio in Q2 2026, its #418 holding.
Algert Global first reported a position in BioMarin Pharmaceuticals in Q4 2022 and has held it in 9 quarters since.
Algert Global's BioMarin Pharmaceuticals position peaked at $9.41M in Q1 2026.
564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.